Alx oncology announces trials in progress abstracts accepted for poster presentation at the society for immunotherapy of cancer (sitc) 37th annual meeting

South san francisco, calif., oct. 05, 2022 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced the acceptance of two trials in progress abstracts related to aspen-03 and aspen-04, the company's phase 2 head and neck cancer studies in collaboration with merck (known as msd outside the us and canada), at the sitc 37th annual meeting in boston, ma, from november 8–12, 2022.
ALXO Ratings Summary
ALXO Quant Ranking